Clinical outcome of patients with pancreatic metastases from renal cell cancer

Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. Of 262 pat...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2015-02, Vol.15 (1), p.46-46, Article 46
Main Authors: Yuasa, Takeshi, Inoshita, Naoko, Saiura, Akio, Yamamoto, Shinya, Urakami, Shinji, Masuda, Hitoshi, Fujii, Yasuhisa, Fukui, Iwao, Ishikawa, Yuichi, Yonese, Junji
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Renal Cell - pathology
Female
Follow-Up Studies
Humans
Kidney Neoplasms - pathology
Male
Middle Aged
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - secondary
Pancreatic Neoplasms - therapy
Retrospective Studies
Risk Factors
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed. The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8-15.5 years) and 3.8 years (IQR, 2.1-5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2-12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-015-1050-2